The incidence of multidrug-resistant tuberculosis (MDR-TB) is increasing in high human immunodeficiency virus (HIV) prevalence settings, with high associated mortality. Treatment outcomes in HIVco-infected adults and children are poorly documented. O B J E C T I V E : To systematically assess treatment outcomes among HIV-MDR-TB co-infected patients.
in adults (95%CI 28-48.1) and 11.4% (95%CI 5.8-17.1) in children. Loss to follow-up was higher among adults (16.1%, 95%CI 9-23.2) than among children (3.9%, 95%CI 0.9-6.9). Adverse events were experienced by the majority of patients; however, this was inconsistently documented. The use of fluoroquinolones, aminoglycosides and Group IV drugs appeared to be associated with treatment success. C O N C L U S I O N : The proportion of HIV-MDR-TB-coinfected patients achieving treatment success was similar to success rates reported among MDR-TB patients in general, regardless of HIV status; however, mortality was higher, particularly among adults, highlighting the need for early diagnosis and more effective treatment regimens. K E Y W O R D S : human immunodeficiency virus/AIDS; multidrug-resistant tuberculosis; meta-analysis; mortality; treatment success MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB, defined as tuberculosis [TB] resistant to both isoniazid and rifampicin [RMP] ) is an escalating problem worldwide. In 2013, the World Health Organization (WHO) estimated that there were 480 000 new MDR-TB cases globally. 1 According to the WHO, progress towards targets for diagnosis and treatment of MDR-TB is off track in several countries, and overall less than half of patients initiating MDR-TB treatment have successful outcomes; 2 however, treatment success rates appear to be higher among children. 3 TB and human immunodeficiency virus (HIV) coinfection is a global health priority. TB is a major cause of death among people living with HIV (PLHIV), and HIV is the main reason for the failure to meet TB control targets in many settings. Of the 27 high MDR-TB burden countries (defined as having .4000 MDR-TB cases and/or with MDR-TB cases representing at least 10% of newly registered TB cases), seven are classified as having a generalised HIV epidemic (HIV firmly established in the general population) and 10 as having a concentrated HIV epidemic (HIV concentrated in sub-populations). 4 There is evidence that TB patients living with HIV are at greater risk of harbouring and acquiring MDR-TB strains, 5 and that HIV-related immunodeficiency is a risk factor for poor outcomes in MDR-TB patients. [6] [7] [8] Current guidance for the use of antiretroviral therapy (ART) in HIV-MDR-TB co-infected patients is largely the same as for HIV-drug-susceptible TB coinfected patients, 9 but treatment of MDR-TB in HIVinfected patients is more challenging: in addition to the long and difficult treatment associated with MDR-TB treatment, HIV-MDR-TB co-infected pa-tients may have additional comorbidities and opportunistic infections, a higher pill burden resulting from the co-administration of anti-tuberculosis and ART drugs, and the potential for additive side effects and drug interactions. 10 We conducted a systematic review and metaanalysis of the available evidence on treatment outcomes among MDR-TB adult and paediatric patients co-infected with HIV, and assessed characteristics of studies and patients that may influence outcomes, particularly treatment success.
METHODS
This study was conducted according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines for the reporting of systematic reviews. 11 As this was a retrospective analysis of data, informed consent from participants was not required.
Eligibility criteria
We sought studies reporting major clinical outcomes in MDR-TB adult and paediatric patients co-infected with HIV. The primary outcome of interest was treatment success, defined as a combination of cure and treatment completion according to WHO definitions. Secondary outcomes were death, loss to follow-up (LFU), transfer, relapse, failure and adverse events. Studies were eligible regardless of language, design and setting, provided they reported any outcomes of at least five HIV-infected patients and described MDR-TB treatment with second-line antituberculosis drugs. We did not restrict the selection to culture-confirmed MDR-TB cases, as bacteriological confirmation was not always possible among HIVinfected patients, particularly children. 12 However, papers focusing on a single presentation of TB, such as MDR-TB meningitis with higher rates of mortality, were excluded to prevent skewing the results for the most relevant question of treatment outcomes across all populations studied. When there were multiple reports from the same cohort, the study with the longest follow-up period was selected.
Information sources and search strategy
We searched Medline via PubMed and Embase from inception to November 2014 using the following search terms as MESH headings and free-text terms: human immunodeficiency, HIV, AIDS, HIV/AIDS, tuberculosis, TB, drug-resistant tuberculosis, multidrug resistance, multidrug-resistant, MDRTB, MDR TB, MDR-TB, treatment, outcome. We further screened all abstracts of the International Union Against Tuberculosis and Lung Disease's World Conferences on Lung Health from 2011 to 2014 to identify studies that had been completed but not yet published as full text. Four investigators (PI, ECC, MD, XT) performed the initial title and abstract screening independently, and relevant abstracts were assessed in full text. Final inclusion was decided through consensus, with disagreements resolved by a fifth investigator (EEN). Bibliographies of full-text articles and previous meta-analyses of treatment outcomes among MDR-TB patients were examined for eligible studies. 3, [13] [14] [15] Authors of relevant studies were contacted for clarification and additional data when necessary.
Data extraction
Information was collected about patients (adults, children), studies (study design, cohort size, setting), treatment protocols (number and type of second-line anti-tuberculosis drugs; individualised or standardised), treatment duration and study outcome definitions. Data on ART initiation were also extracted. All data were extracted independently and in duplicate using a standardised extraction form. We assessed the methodological quality of the included studies and the risk of bias conferred by using elements from the RTI (Research Triangle Institute, Research Triangle Park, NC, USA) item bank. 16 
Data analysis
Point estimates and 95% confidence intervals (95%CIs) were calculated for all primary and secondary outcomes. The denominator for all outcomes was the proportion of patients enrolled and those initiating treatment. The variance of raw proportions was stabilised using a Freeman-Tukey type arc sine square-root transformation; 17 proportions were then pooled using a DerSimonian and Laird random effects model 18 stratified by age. We calculated the s 2 statistic using DerSimonian and Laird's method of moments estimator 18 to assess between-study heterogeneity. 19 Studies reporting single outcomes contributed data to that outcome such that different studies contributed data for different outcomes; however, we also ran an analysis restricted to studies reporting all four major outcomes (treatment success, death, LFU and transfer out). We ran a sensitivity analysis on our primary outcome using a Bayesian random-effects model with Monte Carlo Markov chain simulations of variability. Sources of heterogeneity were explored through preplanned univariate subgroup analyses to assess the potential influence of the following covariates: study setting, study design, regimen (individualised vs. standardised), duration, number of Group IV drugs (,2 vs. 72), use of aminoglycosides (any aminoglycoside vs. no use of aminoglycoside or not reported), use of fluoroquinolones (FQs) (no use of FQ or not reported vs. use of ofloxacin or non-specified use of FQ vs. use of a later generation of FQ), and use of ART drugs. All analyses were conducted using Stata, version 12 (Stata Corp LP, College Station, TX, USA) and Open MetaAnalyst (http://www.cebm.brown. edu/open_meta/download); P 6 0.05 was considered significant.
RESULTS

Characteristics of included studies
A flow chart of the study selection is shown in Figure  1 . Of 4812 abstracts screened, 30 abstracts with data on outcomes on 2578 adults and 147 children [44] [45] [46] [47] [48] between 1990 and 2014 (Table 1) were included in the final review. Characteristics of studies, populations and treatment are given in Table  1 . Cohort size ranged from 7 to 440 patients with HIV and MDR-TB (median 43, interquartile range [IQR] 13-87). Six studies were from high-income settings (United States and Europe), 14 from upper middle-income settings (Argentina, South Africa, Peru, Azerbaijan and Botswana), six from lower middle-income settings (India, Lesotho, Swaziland and Georgia) and three from low-income settings (Haiti, Cambodia and Ethiopia); paediatric studies were from two countries in southern Africa: South Africa and Lesotho. Nine studies did not report use of ART, one reported no use, 10 reported use of ART in all patients (including three paediatric studies) and eight studies reported mixed use. All studies reported some degree of microbiological confirmation of MDR-TB, with 23 studies reporting microbiological confirmation for the entire cohort. Two studies did not provide information on treatment regimen. Treatment duration, as reported by 23 studies, ranged from 8.3 months to 33 months.
Methodological characteristics
All studies used an appropriate study design to answer the research question, and inclusion and exclusion criteria were clearly stated by most studies and were implemented consistently across study participants. Outcome definitions were not clearly stated, and time points for the measurement of the primary outcomes were not consistently defined due to the retrospective nature of the majority of the studies. Finally, it was judged that the investigators assessed outcomes using valid and reliable measures, and the length of follow-up was sufficient to support the conclusions of the study regarding primary outcomes. The main limitations were the retrospective study design of the majority of the studies (n ¼ 19) and the small sample size, which prevent any valid conclusions being drawn regarding the accuracy and precision of the observed estimates.
Primary and secondary outcomes Treatment success, regardless of reporting of other clinical outcomes, was reported by 23 studies, and overall the pooled proportion of patients achieving treatment success was 56.9% (95%CI 46.2-67.6). Among adults, treatment success varied from 12.2% to 98.2%, with a pooled proportion of 49.9% (95%CI 38.5-61.2). Among children, overall success was 83.4% (95%CI 74.8-92) (Figure 2 ). These pooled estimates were the same if a Bayesian approach was taken (successful treatment in 56.6% of patients overall, 95% credible interval 45.9-67.1).
Adult mortality, regardless of the reporting of other clinical outcomes, varied from 1.8% to 87.8%, with a pooled proportion of 38% (95%CI 28-48.1). Child mortality varied from 3.2% to 19%, with a pooled proportion of 11.5% (95%CI 5.9-17.1); overall mortality was 33.5 (95%CI 24.5-42.6) ( Figure 3) .
When analyses were restricted to adult studies reporting all outcomes (treatment success, mortality, LFU and transfer out), results were as follows: 43 (Table 2 ) suggested that the proportion of patients successfully treated did not differ significantly according to design or regimen (individualised vs. standardised). Treatment success did appear to be greater in low-and lower-middle-income countries, when two or more Group IV drugs, aminoglycosides and older or newer generation FQs were included in the regimen. Data were insufficient to explore the potential influence of treatment duration or concomitant ART use.
LFU (20 studies) was significantly higher among adults (16.1%, 95%CI 9-23.2) than among children 
Treatment outcomes in HIV-MDR-TB co-infection
Finally, adverse events were experienced by the majority of adult (83.1%, 95%CI 73.3-92.9) and paediatric (92.5%, 95%CI 83.7-100) patients; however, only five studies provided adequate data to assess the frequency of adverse events.
DISCUSSION
This systematic review of data for 2725 HIV coinfected adult and paediatric patients treated for MDR-TB found that only around half of the patients achieved treatment success. Treatment outcomes were better in children than in adults, consistent with findings reported for non-HIV-co-infected patients. 3 However, mortality among adults was four times higher than reported for HIV-negative populations (38% vs. 11%), while mortality among children was twice as high (11.5% vs. 6%). 13, 15, 49 Among adults, the highest success rates were reported in Azerbaijan 43 and South Africa. 32 The success of these programmes may be attributable to three factors: ensuring adherence with direct observation and/or adherence support; provision of intensive adverse event monitoring; and, in the case of the southern African countries, providing decentralised home-based care and access to ART for all or most co-infected patients. More than 70% of patients in the South African cohorts and 95% of patients in Lesotho were receiving ART during MDR-TB treatment. In children, early identification of patients with presumed MDR-TB through contact tracing, 44 early empiric treatment while waiting for confirmation from drug susceptibility testing (DST) in communitybased programmes, and early ART initiation as soon as patients tolerated MDR-TB treatment were described and were likely to be related to low mortality. 42 Programmes using FQs, especially latergeneration FQs, aminoglycosides and more than two Group IV drugs, showed better success rates. This is similar to reports in the general population, regardless of HIV status. 49 Cohorts reporting the worst outcomes 23,25 and higher mortality 23 were mainly the early cohorts of HIV-MDR-TB co-infected patients when the use of ART was limited. The high mortality among HIV-coinfected individuals underlines the pressing need to improve early diagnosis of both diseases, with access to rapid diagnosis of TB and identification of RMPresistant TB, and to improve the efficacy and safety of drugs to treat MDR-TB. Two new drugs-bedaquiline and delamanid-have been approved for the management of MDR-TB but are not yet widely available for patients in need; other promising drugs are in the research and development pipeline. However, clinical data on the safety, efficacy and drug-drug interactions in co-infected patients, particularly among severely immunocompromised patients and those on concomitant ART, are limited, as coinfected patients are generally excluded from clinical trials. [50] [51] [52] Efforts are needed to ensure that HIVinfected adults and children are included in future clinical trials and observational cohorts.
Adverse events were reported inconsistently, underscoring the need for standardisation of reporting adverse events. As studies reporting only adverse events but no other outcomes were not included, it is not possible to draw major conclusions. However, there is a need to better understand the risks associated with co-administration of MDR-TB treatment and ART, as the high mortality reported by this review supports current recommendations to treat HIV and MDR-TB concomitantly, similar to drugsusceptible TB.
A detailed analysis of the impact of ART was not possible due to the variability in the reporting of access to ART; this was due to the inclusion of cohorts from the pre-ART era, differing recommendations regarding ART use in co-infected patients and poor study reporting. Microbiological confirmation was often not possible in HIV-infected patients and young children; also, the inclusion of unconfirmed cases in the studies included in this meta-analysis might have introduced bias. Another limitation of the evidence base was that most studies did not differentiate between the inclusion/exclusion of patients with second-line drug resistance, mostly due to the lack of access to second-line DST, either because cohorts were from earlier periods or because settings currently lacked access to second-line DST. This might partly explain the heterogeneity in treatment success rates across studies.
We used a broad search strategy that allowed the identification of studies reporting outcomes across populations and settings; however, despite the high disease burden very few data are available, particularly among paediatric patients. The inclusion of data from a range of settings resulted in considerable heterogeneity, which was compensated for by using random-effects analysis and undertaking subgroup analyses; however, such analyses were also limited by the inconsistent reporting of important study characteristics, in particular baseline immune status, type of MDR-TB treatment regimen and concomitant ART. In this review, we chose to include any reported outcomes to prevent loss of information, as can be appreciated from the fact that the analysis was restricted to studies reporting all outcomes. This review summarises published outcomes, which may not be representative of all outcomes achieved in routine programme settings. Finally, the review only considers outcomes among patients who initiated MDR-TB treatment; MDR-TB treatment coverage remains inadequate in most high-burden countries, 2 and substantial mortality occurs among people who have not been able to start treatment.
In conclusion, the findings of this systematic review and meta-analysis indicate high mortality in HIV-MDR-TB co-infected patients, underscoring the urgent need to improve on current approaches to diagnosis and treatment. Early identification of HIV to allow early initiation of ART, early diagnosis of MDR-TB with improved access to resistance testing for HIV-TB co-infected patients, and access to second-line anti-tuberculosis drugs, are critical to increase the likelihood of treatment success and survival among HIV-MDR-TB co-infected populations. HIV-infected adults and children should be included in future clinical trials and observational cohorts to ensure that the necessary data are generated to allow these vulnerable populations to benefit from advances in treatment. 9) . La majorité des patients a connu des effets indésirables ; cependant, ceux-ci n'ont pasété documentés de façon cohérente. L'utilisation de fluoroquinolones, d'aminosides et de médicaments du Groupe IV semblent avoirété associée avec le succès du traitement. C O N C L U S I O N S : La proportion de patients co-infectés par une TB-MDR et par le VIH dont le traitement a réussi est similaire au taux de succès rapporté pour les patients TB-MDR, quel que soit leur statut VIH, mais la mortalité est plusélevée, surtout parmi les adultes, ce qui souligne le besoin de diagnostic précoce et de protocoles de traitement plus efficaces.
R E S U M E N M A R C O D E R E F E R E N C I A:
La incidencia de tuberculosis multidrogorresistente (TB-MDR) está aumentando en los entornos con alta prevalencia de infección por el virus de la inmunodeficiencia humana (VIH) y se asocia con una alta mortalidad. Existe poca documentación sobre los desenlaces terapéuticos en los adultos y los niños coinfectados por el VIH. O B J E T I V O: Evaluar de manera sistemá tica los desenlaces de pacientes coinfectados por el VIH y la TB-MDR. M E T O D O S: Se llevó a cabo una búsqueda en dos bases de datos y en las comunicaciones de una conferencia internacional anual hasta noviembre del 2014, de estudios sobre los principales desenlaces clínicos de los adultos y los niños coinfectados por el VIH y la TB-MDR y se agregaron los resultados mediante un aná lisis de efectos aleatorios. R E S U LT A D O S: De los 4812 resúmenes y artículos examinados, se retuvieron 30 estudios con datos sobre 2578 adultos y 147 niños. Eléxito terapéutico global agregado fue 56,9% (IC95% 46,2-67,6), 49,9% en los adultos (IC95% 38,5-61,2) y 83,4% en los niños (IC95% 74,7-92). Se observó una mortalidad de 38% en los adultos (IC95% 28-48,1) y 11,4% en los niños (IC95% 5,8-17,1). La pérdida durante el seguimiento fue má s alta en los adultos (16,1 %; IC95% 9-23,2) que en los niños (3,9%; IC95% 0,9-6,9). La mayoría de los pacientes presentó reacciones adversas; sin embargo, la documentación de este acontecimiento fue inconstante. El uso de fluoroquinolonas, aminoglucósidos y medicamentos del Grupo IV resultó asociado con eĺ exito terapéutico. C O N C L U S I O N: La proporción de pacientes coinfectados por el VIH y la TB-MDR que alcanzó eléxito terapéutico fue equivalente a las tasas deéxito notificadas en los pacientes TB-MDR sin consideración de su situación frente al VIH, pero la mortalidad fue má s alta, sobre todo en los adultos, lo cual destaca la necesidad de un diagnóstico temprano y de regímenes terapéuticos má s eficaces.
